Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.69 |
| ▸ | LPL | P06858 | 12/20 | 0.69 |
| ▸ | F11 | P03951 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | P4HB | P07237 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23750301 | 1.00 | LIPG (0.69) | LIPGLPLF11CA1CA2 | |
| SCHEMBL102562 | 0.94 | LIPG (0.59) | LIPGLPLF11CA1CA2 | |
| SCHEMBL2707320 | 0.89 | LIPG (0.83) | LIPGLPLF11CA1CA2 | |
| SCHEMBL24608995 | 0.89 | LIPG (0.83) | LIPGLPLF11CA1CA2 | |
| SCHEMBL17952428 | 0.84 | LIPG (0.50) | LIPGLPLF11ESR1ESR2 | |
| SCHEMBL28389622 | 0.83 | LIPG (0.88) | LIPGLPLF11CA1CA2 | |
| SCHEMBL12681706 | 0.83 | LIPG (0.74) | LIPGLPLF11CA1CA2 | |
| SCHEMBL15476363 | 0.83 | P4HB (0.56) | LIPGLPLF11CA1CA2 | |
| SCHEMBL19729193 | 0.83 | LIPG (0.69) | LIPGLPLF11CA1CA2 | |
| SCHEMBL19729194 | 0.83 | LPL (0.49) | LIPGLPLF11CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667509-A1 | POLYMER, ELECTROLYTE MATERIAL, ELECTROLYTE MEMBRANE, ELECTROLYTE MEMBRANE WITH CATALYST LAYER, MEMBRANE ELECTRODE ASSEMBLY, SOLID POLYMER FUEL CELL, AND SOLID POLYMER WATER ELECTROLYSIS DEVICE | Tosoh Corporation (JP) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024204267-A1 | POLYMER, ELECTROLYTE MATERIAL, ELECTROLYTE MEMBRANE, ELECTROLYTE MEMBRANE WITH CATALYST LAYER, MEMBRANE ELECTRODE ASSEMBLY, SOLID POLYMER FUEL CELL, AND SOLID POLYMER WATER ELECTROLYSIS DEVICE | 東ソー株式会社 | 2024-10-03 | — | — | WO | disclosed |
| WO-2024153107-A1 | COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND USE THEREOF, AND ORGANIC ELECTROLUMINESCENT DEVICE | 北京鼎材科技有限公司 | 2024-07-25 | — | — | WO | disclosed |
| CN-113549010-B | Preparation and application of compound with AMPK (AMPK) agonistic activity and prodrug thereof | 中国科学院上海药物研究所 | 2023-10-20 | — | — | CN | disclosed |
| CN-115417823-A | Preparation method of pyrimidine biphenyl aromatic ring compound | 上海泰坦科技股份有限公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-113549010-A | Preparation and application of compound with AMPK agonistic activity and prodrug thereof | 中国科学院上海药物研究所 | 2021-10-26 | — | — | CN | disclosed |
| US-10478425-B2 | 5-phenylazaindole derivative having AMPK-activating activity | SHIONOGI & CO., LTD. (JP) | 2019-11-19 | — | — | US | disclosed |
| EP-3421467-A1 | 5-PHENYLAZAINDOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT | Shionogi & Co., Ltd (JP) | 2019-01-02 | — | — | EP | disclosed |
| WO-2017146186-A1 | 5-PHENYLAZAINDOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT | 塩野義製薬株式会社 | 2017-08-31 | — | — | WO | disclosed |
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | LIPG 2720/4885LPL 4512/4885F11 2252/4885 |
| US-10478425-B2 | 5-phenylazaindole derivative having AMPK-activating activity | PRKAG2, PRKAG1, PRKAB2 | LIPG 2637/4885LPL 404/4885F11 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.